Several aspects of recreational cannabis sales, regulation, and sales have not been finalized, despite its legalization months prior.
Cannabis for recreational purposes is still not available for purchase in Ohio—two months after voters passed Issue 2, which legalized the possession and use of cannabis for adults over the age of 21 (1,2). The state’s Division of Cannabis Control, created after the passing of Issue 2, recently proposed granting licenses for medical cannabis dispensaries to sell both medical and recreational cannabis (2).
“Currently there are no individuals or entities licensed to sell non-medical cannabis in the state of Ohio, and any sale of marijuana prior to non-medical licenses being issued may be subject to criminal penalties,” read a bolded statement on the Division’s website in the “Non-Medical Cannabis FAQ” section (3).
Medical cannabis would still be regulated under the state’s Medical Marijuana Control Program, even with the potential for dually-licensed dispensaries (2).
“We are ready to implement it overnight,” said Nilendu Singh, owner of Nar Dispensary in Columbus, Ohio (1). “I think that is where a lot of dispensaries are at too and Nar reserve is no different. The moment we get that license or we know we are getting it, we will be ready to roll it out that day.”
Ohio governor Mike DeWine has encouraged the passing of HB 86 by the House, which would make the sale of recreational cannabis legal in the state and increase the tax to 15% (1). Last month, the governor also held a press conference urging the passing of legislation that would make the sale of delta-8 products to anyone under 21, specifically children, illegal (3).
Packaging and licensing of delta-8 products would then become regulated alongside recreational cannabis (3). "The biggest concern we have is it is a product that looks like it should be consumed by a child,” DeWine said (3). “It is a product that is advertised by the packaging as if it is for a child. None of those things could occur if it was under the protocol of the sale of marijuana.” Currently, these products are available for purchase at locations including gas stations and vape stores (3).
Learn the latest about hemp-derived cannabinoids our coverage of the GMP Collective webinar, “Intoxicating Hemp and Synthetic Cannabinoids: Insights into Lab Testing.”
Track the recent history of recreational cannabis legislation in Ohio here.
References
Ep 25: Cannabis Quality Differentiation Beyond Cannabinoid Content
February 28th 2025In this latest installment of Noid Knowledge we are joined by Julie Kowalski, a leading mind in analytical chemistry and cannabis testing. Julie has arranged a very compelling symposium for Pittcon entitled Cannabis Aroma: Advances and Challenges in Determining and Commercializing Cannabis Product Quality Attributes. It is taking place on Wednesday, March 5, 2025, starting at 9:30 AM in room 209. The session features top notch speakers, including several previous guests of this show, and yours truly, discussing the next generation of quality assessment in cannabis.
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.